BIOMARKER SIGNIFICANCE OF CIRCULATING DNA ACCORDING TO LIQUID BIOPSY IN PATIENTS WITH PREGNANCY-ASSOCIATED CANCER AND UROGENICOLOGICAL CANCER

Authors:

Abstract:

The purpose of the study was to investigate the role of the biomarker of circulating cell-free DNA in the the development of pregnancy-associated renal cell carcinoma and pregnancy-associated uterine sarcoma within 1 years (56 weeks) after childbirth. To test our hypothesis, this case-control study consisted of the indicators of cfDNA in the blood serum of 16 patients with pregnancy-associated renal cell carcinoma; 38 patients with renal cell carcinoma; 8 patients with pregnancy-associated uterine sarcoma and 11 patients with uterine sarcoma. We have established a high level of circulating cell-free DNA in sick women, both renal cell carcinoma and uterine sarcoma, as well as the pregnancy-associated renal cell carcinoma and pregnancy-associated uterine sarcoma, at all stages of the tumor process. in our study, The mathematical prognostic model of changing circulating cell-free DNA levels in women during the year after childbirth within 26–36 weeks and 40–41 weeks, confirmed a high and moderate risk of developing pregnancy-associated cancer in the first 12–24 weeks after childbirth, which corresponds to the time diagnostics of the pregnancy-associated cancer in our study. The pathogenetic platform of the development of pregnancy-associated cancer is a high level of circulating cell-free DNA in women during pregnancy and the first 12–24 weeks after birth in a period of 40–41 weeks and especially with premature birth in 26–36 weeks

Keywords:

Array Array Array

References:

1. Crigna AT, Samec M, Koklesova L. Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope? EPMA J. 2020;11(4):603-627. doi:10.1007/s13167-020-00226-x.
2. Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology. 2017 Dec;71(6):918-925. doi: 10.1111/his.13311.
3. Guan HB, Wu QJ, Gong TT. Parity and kidney cancer risk: evidence from epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2013; 22: 2345–53. https://doi.org/10.1158/1055-9965.EPI-13-0759-T.
4. Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med. 2012 Aug 8;10:86. doi: 10.1186/1741-7015-10-86.
5. Heesterbeek CJ, Tjan-Heijnen VCG, Heimovaara JH, Lenaerts L, Lok C, Vriens IJH, et al. Dutch NIPT Consortium. Prenatal cell-free DNA testing of women with pregnancy-associated cancer: a retrospective cross-sectional study. Lancet Reg Health Eur. 2024 Aug 7;45:101024. doi: 10.1016/j.lanepe.2024.101024.
6. Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine Sarcoma Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database. Intern.J.Gynecological cancer. 2016; 26(6): P1098-1104. DOI: 10.1097/IGC.0000000000000720.
7. ICD-0–3. SEER Site/Histology Validation December 5 2012:301-496 Available at http://seer.cancer.gov/icd-o-3/.
8. Kemenade FJ. Incidental findings in NIPT show potential for detecting hematological malignancies. Lancet Reg Health Eur. 2024 Aug 30;45:101045. doi: 10.1016/j.lanepe.2024.101045.
9. Komarevtseva IO, Posternak DG, Cherednichenko RV, Shatrova AS, Chernykh YuA, Balabanova KV, et al. Circulating cell-free DNA is biomarker of premature birth and COVID-19 and predicts of prenatal cerebral ischemia in newborns. World of Medicine and Biology. 2022; 79(1): 079-084. doi: 10.26724/2079-8334-2022-1-79-79-84.
10. Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara CM, Sæther SMM, et al. The Role of Pregnancy, Perinatal Factors, and Hormones in Maternal Cancer Risk: A review of the evidence. J Intern Med. 2018 Mar 25;283(5):430-445. doi: 10.1111/joim.12747.
11. Yamamoto Y, Uemura M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, et al. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. Oncotarget. 2018 Apr 17;9(29):20467-20475. doi: 10.18632/oncotarget.24943.

Publication:

«World of Medicine and Biology» Vol. 21 No. 91 (2025) , с. 65-71
УДК 616.61-006:616.65+576.367

DOI:

https://doi.org/10.26724/2079-8334-2025-1-91-65-71